XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 42.59

Change

-0.53 (-1.23)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.77 (-0.53%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.51 (-0.75%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.85 (-0.82%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-1.50 (-1.81%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.21 (-0.96%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.50 (-1.61%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.99 (-1.05%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.58 (-2.06%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.59 (-0.98%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.59 (-2.91%)

USD 6.67M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.03 % 0.00 %

-0.27 (-1.00%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.93% 43% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.93% 43% F 50% F
Trailing 12 Months  
Capital Gain 0.47% 67% D+ 46% F
Dividend Return 1.60% 100% F 29% F
Total Return 2.07% 71% C- 39% F
Trailing 5 Years  
Capital Gain 16.75% 29% F 42% F
Dividend Return 7.04% 68% D+ 14% F
Total Return 23.79% 33% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -2.27% 19% F 22% F
Dividend Return -1.48% 29% F 15% F
Total Return 0.78% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.43% 67% D+ 65% D
Risk Adjusted Return -9.62% 19% F 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.